Loading profile…
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
DBA: N/A
EIN 81-1547477 · Snapshot of IRS recognition, filing currency, financial health, and governance.
Research and Development of pharmaceutical treatments to help eliminate neglected tropical diseases especially Oxfendazole through nonclinical work and the conduct of clinical studies
Principal Officer
R John Horton
Total Revenue
$9K
FY2025
Total Expenses
$227K
FY2025
Net Assets
$100K
Program Ratio
99.4%
expenses on programs
Employees
0
Volunteers
9
Board Members
5
Voting
5
Independent
8 answers compiled from IRS Form 990, BMF, Pub 78, and the Auto-Revocation List.